PMID- 27598967 OWN - NLM STAT- MEDLINE DCOM- 20171107 LR - 20201209 IS - 2158-3188 (Electronic) IS - 2158-3188 (Linking) VI - 6 IP - 9 DP - 2016 Sep 6 TI - Genome-wide association study of antisocial personality disorder. PG - e883 LID - 10.1038/tp.2016.155 [doi] AB - The pathophysiology of antisocial personality disorder (ASPD) remains unclear. Although the most consistent biological finding is reduced grey matter volume in the frontal cortex, about 50% of the total liability to developing ASPD has been attributed to genetic factors. The contributing genes remain largely unknown. Therefore, we sought to study the genetic background of ASPD. We conducted a genome-wide association study (GWAS) and a replication analysis of Finnish criminal offenders fulfilling DSM-IV criteria for ASPD (N=370, N=5850 for controls, GWAS; N=173, N=3766 for controls and replication sample). The GWAS resulted in suggestive associations of two clusters of single-nucleotide polymorphisms at 6p21.2 and at 6p21.32 at the human leukocyte antigen (HLA) region. Imputation of HLA alleles revealed an independent association with DRB1*01:01 (odds ratio (OR)=2.19 (1.53-3.14), P=1.9 x 10(-5)). Two polymorphisms at 6p21.2 LINC00951-LRFN2 gene region were replicated in a separate data set, and rs4714329 reached genome-wide significance (OR=1.59 (1.37-1.85), P=1.6 x 10(-9)) in the meta-analysis. The risk allele also associated with antisocial features in the general population conditioned for severe problems in childhood family (beta=0.68, P=0.012). Functional analysis in brain tissue in open access GTEx and Braineac databases revealed eQTL associations of rs4714329 with LINC00951 and LRFN2 in cerebellum. In humans, LINC00951 and LRFN2 are both expressed in the brain, especially in the frontal cortex, which is intriguing considering the role of the frontal cortex in behavior and the neuroanatomical findings of reduced gray matter volume in ASPD. To our knowledge, this is the first study showing genome-wide significant and replicable findings on genetic variants associated with any personality disorder. FAU - Rautiainen, M-R AU - Rautiainen MR AD - National Institute for Health and Welfare, Department of Health, Helsinki, Finland. AD - Department of Forensic Psychiatry, Niuvanniemi Hospital, University of Eastern Finland, Kuopio, Finland. AD - Department of Psychiatry, University of Helsinki, Helsinki, Finland. AD - Department of Psychiatry, Helsinki University Hospital, Helsinki, Finland. FAU - Paunio, T AU - Paunio T AD - National Institute for Health and Welfare, Department of Health, Helsinki, Finland. AD - Department of Psychiatry, University of Helsinki, Helsinki, Finland. AD - Department of Psychiatry, Helsinki University Hospital, Helsinki, Finland. AD - Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland. FAU - Repo-Tiihonen, E AU - Repo-Tiihonen E AD - Department of Forensic Psychiatry, Niuvanniemi Hospital, University of Eastern Finland, Kuopio, Finland. FAU - Virkkunen, M AU - Virkkunen M AD - Department of Psychiatry, University of Helsinki, Helsinki, Finland. AD - Department of Psychiatry, Helsinki University Hospital, Helsinki, Finland. FAU - Ollila, H M AU - Ollila HM AD - National Institute for Health and Welfare, Department of Health, Helsinki, Finland. AD - Stanford University Center for Sleep Sciences, Palo Alto, CA, USA. FAU - Sulkava, S AU - Sulkava S AD - National Institute for Health and Welfare, Department of Health, Helsinki, Finland. AD - Department of Psychiatry, University of Helsinki, Helsinki, Finland. AD - Department of Psychiatry, Helsinki University Hospital, Helsinki, Finland. FAU - Jolanki, O AU - Jolanki O AD - Stanford University Center for Sleep Sciences, Palo Alto, CA, USA. FAU - Palotie, A AU - Palotie A AD - Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland. AD - Wellcome Trust Sanger Institute, Hinxton, UK. AD - Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. AD - Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA. AD - Psychiatric and Neurodevelopmental Genetics Unit, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA. FAU - Tiihonen, J AU - Tiihonen J AD - Department of Forensic Psychiatry, Niuvanniemi Hospital, University of Eastern Finland, Kuopio, Finland. AD - Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. LA - eng PT - Journal Article DEP - 20160906 PL - United States TA - Transl Psychiatry JT - Translational psychiatry JID - 101562664 RN - 0 (Cell Adhesion Molecules) RN - 0 (HLA Antigens) RN - 0 (HLA-DR alpha-Chains) RN - 0 (HLA-DRB1 Chains) RN - 0 (HLA-DRB1*01:01 antigen) RN - 0 (LRFN2 protein, human) RN - 0 (Membrane Glycoproteins) RN - 0 (Membrane Proteins) RN - 0 (Nerve Tissue Proteins) RN - 0 (RNA, Long Noncoding) RN - 0 (SDK1 protein, human) SB - IM MH - Adult MH - Antisocial Personality Disorder/*genetics/metabolism/pathology MH - Brain/metabolism MH - Case-Control Studies MH - Cell Adhesion Molecules/genetics MH - Cerebellum/metabolism MH - Chromosomes, Human, Pair 6/*genetics MH - Criminals MH - Female MH - Finland MH - Frontal Lobe/metabolism MH - Genome-Wide Association Study MH - Gray Matter/metabolism/pathology MH - HLA Antigens/*genetics MH - HLA-DR alpha-Chains/genetics MH - HLA-DRB1 Chains/genetics MH - Humans MH - Male MH - Membrane Glycoproteins MH - Membrane Proteins/genetics/metabolism MH - Nerve Tissue Proteins MH - Odds Ratio MH - Organ Size MH - Polymorphism, Single Nucleotide MH - RNA, Long Noncoding/*genetics/metabolism PMC - PMC5048197 EDAT- 2016/09/07 06:00 MHDA- 2017/11/08 06:00 PMCR- 2016/09/01 CRDT- 2016/09/07 06:00 PHST- 2015/10/26 00:00 [received] PHST- 2016/06/20 00:00 [revised] PHST- 2016/07/16 00:00 [accepted] PHST- 2016/09/07 06:00 [entrez] PHST- 2016/09/07 06:00 [pubmed] PHST- 2017/11/08 06:00 [medline] PHST- 2016/09/01 00:00 [pmc-release] AID - tp2016155 [pii] AID - 10.1038/tp.2016.155 [doi] PST - epublish SO - Transl Psychiatry. 2016 Sep 6;6(9):e883. doi: 10.1038/tp.2016.155.